Pharmacotherapeutic targets in Alzheimer's disease

•  Current pharmacotherapies for the treatment of AD •  AD pharmacotherapies targeting τ ‐  Modulators of – kinases or phosphatases ‐  τ aggregation inhibitors (TAIs) •  AD pharmacotherapies targeting Aβ ‐  Inhibitors and/or modulators of the secretases ‐  Aβ aggregation inhibitors ‐  Passive or active immunization •  The metal hypothesis of AD •  AD pharmacotherapies targeting metal ions ‐  Antioxidants ‐  Metal chelators ‐  Metal complexes ‐  Metal‐protein attenuating compounds

• Publication year

  2008

• Venue

  Journal of Cellular and Molecular Medicine

• Publication date

  2008-11-18

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1582-4934.2008.00595.xPMID 19040415PMCID 3823037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic perspectives in Alzheimer's disease.

  2012cited by this paper
• The functions of the amyloid precursor protein gene.

  2011cited by this paper
• Metals and Alzheimer's Disease

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Synthesis and activity of fibrillogenesis peptide inhibitors related to the 17-21 beta-amyloid sequence.

  2009cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42.

  2008cited by this paper
• Neurotoxicity in Alzheimer's disease: is covalently crosslinked A beta responsible?

  2008cited by this paper
• Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.

  2008cited by this paper
• NMR studies of the Zn2+ interactions with rat and human beta-amyloid (1-28) peptides in water-micelle environment.

  2008cited by this paper
• Oligomeric amyloid-β peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism

  2008cited by this paper
• Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease

  2008cited by this paper
• X-ray absorption and diffraction studies of the metal binding sites in amyloid β-peptide

  2008cited by this paper
• Selective Intracellular Release of Copper and Zinc Ions from Bis(thiosemicarbazonato) Complexes Reduces Levels of Alzheimer Disease Amyloid-β Peptide*

  2008cited by this paper
• Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.

  2008cited by this paper
• Evidence That the ZNT3 Protein Controls the Total Amount of Elemental Zinc in Synaptic Vesicles

  2008cited by this paper
• Metals in neurobiology: probing their chemistry and biology with molecular imaging.

  2008cited by this paper
• Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

  2008cited by this paper
• Molecular modeling of zinc and copper binding with Alzheimer’s amyloid β-peptide

  2008cited by this paper
• Molecular modeling of zinc and copper binding with Alzheimer's amyloid beta-peptide.

  2008cited by this paper
• Stabilization of Neurotoxic Soluble β-Sheet-Rich Conformations of the Alzheimer's Disease Amyloid-β Peptide

  2008cited by this paper
• X-ray absorption and diffraction studies of the metal binding sites in amyloid beta-peptide.

  2008cited by this paper
• Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity.

  2008cited by this paper
• Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity.

  2008cited by this paper
• Therapeutics for Alzheimer’s disease based on the metal hypothesis

  2008cited by this paper
• Twenty years of metallo-neurobiology: where to now?

  2008cited by this paper
• Platinum-based inhibitors of amyloid-β as therapeutic agents for Alzheimer's disease

  2008cited by this paper
• Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

  2008cited by this paper
• Metals in Alzheimer's and Parkinson's diseases.

  2008cited by this paper
• Neurotoxicity in Alzheimer’s disease: is covalently crosslinked Aβ responsible?

  2008cited by this paper
• AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders.

  2008cited by this paper
• Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

  2008cited by this paper
• Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide.

  2008cited by this paper
• Binding of zinc(II) and copper(II) to the full‐length Alzheimer’s amyloid‐β peptide

  2008cited by this paper
• Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease.

  2008cited by this paper
• Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation.

  2007cited by this paper
• Clearance of amyloid-beta by circulating lipoprotein receptors.

  2007cited by this paper
• Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.

  2007cited by this paper
• The aggregated state of amyloid-beta peptide in vitro depends on Cu2+ ion concentration.

  2007cited by this paper
• Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra

  2007cited by this paper
• Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau

  2007cited by this paper
• Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.

  2007cited by this paper
• Pyrrolidine Dithiocarbamate Activates Akt and Improves Spatial Learning in APP/PS1 Mice without Affecting β-Amyloid Burden

  2007cited by this paper
• Vibrational spectra of clioquinol and its Cu(II) complex

  2007cited by this paper
• Pharmacokinetics and distribution of clioquinol in golden hamsters

  2007cited by this paper
• Cholesterol metabolism and brain amyloidosis: evidence for a role of copper in the clearance of Abeta through the liver.

  2007cited by this paper
• The redox chemistry of the Alzheimer's disease amyloid β peptide

  2007cited by this paper
• Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template.

  2007cited by this paper
• Clearance of amyloid-β by circulating lipoprotein receptors

  2007cited by this paper
• Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide.

  2007cited by this paper
• Redox Reactions of Copper Complexes Formed with Different β-Amyloid Peptides and Their Neuropathalogical Relevance†

  2007cited by this paper
• The lipophilic metal chelators DP‐109 and DP‐460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis

  2007cited by this paper
• Internalization of β-Amyloid Peptide by Primary Neurons in the Absence of Apolipoprotein E*

  2007cited by this paper
• Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.

  2007cited by this paper
• Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits.

  2007cited by this paper
• Zinc lowers amyloid-beta toxicity by selectively precipitating aggregation intermediates.

  2007cited by this paper
• MDR1‐P‐Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s Amyloid‐β Peptides—Implications for the Mechanisms of Aβ Clearance at the Blood–Brain Barrier

  2007cited by this paper
• Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention

  2007cited by this paper
• Oral administration of metal chelator ameliorates motor dysfunction after a small hemorrhage near the internal capsule in rat

  2007cited by this paper
• Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model

  2007cited by this paper
• Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics.

  2007cited by this paper
• High‐resolution NMR studies of the zinc‐binding site of the Alzheimer's amyloid β‐peptide

  2007cited by this paper
• Autophagy, amyloidogenesis and Alzheimer disease

  2007cited by this paper
• Role of aspartate-1 in Cu(II) binding to the amyloid-beta peptide of Alzheimer's disease.

  2007cited by this paper
• Clioquinol attenuates zinc-dependent beta-cell death and the onset of insulitis and hyperglycemia associated with experimental type I diabetes in mice.

  2007cited by this paper
• N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy.

  2007cited by this paper
• Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis

  2007cited by this paper
• Intracellular amyloid-beta in Alzheimer's disease.

  2007cited by this paper
• Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity

  2007cited by this paper
• Copper (II) modulates in vitro aggregation of a tau peptide.

  2007cited by this paper
• Functionalized bis(thiosemicarbazonato) complexes of zinc and copper: synthetic platforms toward site-specific radiopharmaceuticals.

  2007cited by this paper
• The modulation of metal bio‐availability as a therapeutic strategy for the treatment of Alzheimer's disease

  2007cited by this paper
• Copper and iron disorders of the brain.

  2007cited by this paper
• Redox reactions of copper complexes formed with different beta-amyloid peptides and their neuropathological [correction of neuropathalogical] relevance.

  2007cited by this paper
• Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System

  2007cited by this paper
• Clioquinol and vitamin B12 (cobalamin) synergistically rescue the lead-induced impairments of synaptic plasticity in hippocampal dentate gyrus area of the anesthetized rats in vivo.

  2007cited by this paper
• The redox chemistry of the Alzheimer's disease amyloid beta peptide.

  2007cited by this paper
• Zinc-binding compounds induce cancer cell death via distinct modes of action.

  2007cited by this paper
• Interactions between metals and α‐synuclein − function or artefact?

  2007cited by this paper
• Inhibition of tau aggregation in cell models of tauopathy.

  2007cited by this paper
• Effects of zinc binding on the conformational distribution of the amyloid-beta peptide based on molecular dynamics simulations.

  2007cited by this paper
• High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide.

  2007cited by this paper
• Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease.

  2007cited by this paper
• Intracellular amyloid-β in Alzheimer's disease

  2007cited by this paper
• Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease.

  2007cited by this paper
• Pharmacological strategies for the prevention of Alzheimer’s disease

  2006cited by this paper
• Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism

  2006cited by this paper
• M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

  2006cited by this paper
• Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway.

  2006cited by this paper
• Zoom in on neurodegeneration

  2006cited by this paper
• Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.

  2006cited by this paper
• Antioxidant pyrrolidine dithiocarbamate activates Akt-GSK signaling and is neuroprotective in neonatal hypoxia-ischemia.

  2006influential reference
• Structural and thermodynamical properties of CuII amyloid-β16/28 complexes associated with Alzheimer’s disease

  2006cited by this paper
• Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis).

  2006cited by this paper
• Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.

  2006cited by this paper
• Alzheimer disease: progress or profit?

  2006cited by this paper
• Autophagy in neurodegenerative disease: friend, foe or turncoat?

  2006cited by this paper
• Current Pharmacotherapy for Alzheimer ’ s Disease

  2006cited by this paper
• Solution 1H NMR investigation of Zn2+ and Cd2+ binding to amyloid-beta peptide (Abeta) of Alzheimer's disease.

  2006cited by this paper
• A&bgr; Species Removal After A&bgr;42 Immunization

  2006cited by this paper

• Synthesis, in vitro activity, and molecular docking of caffeic acid and resveratrol derivatives against Alzheimer’s disease-related enzymes

  2024cites this paper
• Proteostasis disruption and senescence in Alzheimer's disease pathways to neurodegeneration.

  2024cites this paper
• Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives

  2023cites this paper
• The amyloid cascade hypothesis: an updated critical review.

  2023cites this paper
• Synthesis and Biological Evaluation of Benzoxazolone−Thiosemicarbazide, 1,2,4‐Triazole, 1,3,4‐Thiadiazole Derivatives as Cholinesterase Inhibitors

  2023cites this paper
• Green Tea Suppresses Amyloid β Levels and Alleviates Cognitive Impairment by Inhibiting APP Cleavage and Preventing Neurotoxicity in 5XFAD Mice.

  2021cites this paper
• Alzheimer Hastalığı Tedavisindeki Güncel Yaklaşımlar

  2021cites this paper
• Target Enzyme in Alzheimer's Disease: Acetylcholinesterase Inhibitors.

  2019cites this paper
• Development of coumarin–benzofuran hybrids as versatile multitargeted compounds for the treatment of Alzheimer’s Disease

  2018cites this paper
• The mechanism of action of clioquinol for the treatment of Alzheimer's disease

  2018cites this paper
• Design and synthesis of some new carboxamide and propanamide derivatives bearing phenylpyridazine as a core ring and the investigation of their inhibitory potential on in-vitro acetylcholinesterase and butyrylcholinesterase.

  2018cites this paper
• Virtual screening of some heterocyclic structures toward novel antibacterial agents

  2018cites this paper
• Acid-base fractions separated from Streblus asper leaf ethanolic extract exhibited antibacterial, antioxidant, anti-acetylcholinesterase, and neuroprotective activities

  2018cites this paper
• Management of Alzheimers Disease: Role of Existing Therapies, Traditional Medicines and New Treatment Targets

  2017influential citation
• Alzheimer's Drug Discovery Maze: A Snap View of the Past Decade's Diverse Pharmacological Targets for the Disorder.

  2017cites this paper
• Phytochemical, Synthetic and Biological Studies on Stemona and Stichoneuron Plants and Alkaloids: A Personal Perspective

  2017cites this paper
• Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25–35-induced Rat Model of Alzheimer’s Disease

  2017cites this paper
• Chameleon sequences in neurodegenerative diseases

  2016cites this paper
• Astrocytes in physiological aging and Alzheimer's disease.

  2016cites this paper
• Antioxidant and Anticholinesterase Potential of Six Thymus Species

  2015cites this paper
• (-)-Meptazinol-melatonin hybrids as novel dual inhibitors of cholinesterases and amyloid-β aggregation with high antioxidant potency for Alzheimer's therapy.

  2015cites this paper
• Synthesis of some 3(2H)-pyridazinone and 1(2H)-phthalazinone derivatives incorporating aminothiazole moiety and investigation of their antioxidant, acetylcholinesterase, and butyrylcholinesterase inhibitory activities

  2015cites this paper
• Acetylcholinesterase inhibitory and antioxidant properties of roots extracts from the Tunisian Scabiosa arenaria Forssk

  2015cites this paper
• Design, synthesis and bioevaluation of tacrine hybrids with cinnamate and cinnamylidene acetate derivatives as potential anti-Alzheimer drugs

  2015cites this paper
• Synthesis of 2-pyridyl-benzimidazole iridium(III), ruthenium(II), and platinum(II) complexes. study of the activity as inhibitors of amyloid-β aggregation and neurotoxicity evaluation.

  2015cites this paper
• Inhibitors of Alzheimer’s BACE-1 with 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridine structure

  2015cites this paper
• Dementia resulting from traumatic brain injury

  2015cites this paper
• Inhibitors of Alzheimer’s BACE-1 with 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridine structure

  2014cites this paper
• Acetylcholinesterase Inhibitory, Antioxidant and Phytochemical Properties of Selected Medicinal Plants of the Lamiaceae Family

  2014cites this paper
• Prion and Prion-like Diseases in Humans

  2014cites this paper
• Ligand Design to Target and Modulate Metal–Protein Interactions in Neurodegenerative Diseases

  2014cites this paper
• 'Click' assembly of glycoclusters and discovery of a trehalose analogue that retards Aβ40 aggregation and inhibits Aβ40-induced neurotoxicity.

  2014cites this paper
• Development of plasma Aβ assays for disease modifying approaches in Alzheimer’s disease

  2013influential citation
• Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

  2013cites this paper
• Copper in Brain and Neurodegeneration

  2013cites this paper
• Multifunctional iron-chelators with protective roles against neurodegenerative diseases.

  2013cites this paper
• INHIBITION OF ACETYLCHOLINESTERASE ACTIVITY BY HIDROALCOHOLIC EXTRACT AND THEIR FRACTIONS OF BOUVARDIA TERNIFOLIA (CAV.) SHCLTDL (RUBIACEAE).

  2012influential citation
• Metal Chaperones: A Holistic Approach to the Treatment of Alzheimer’s Disease

  2012cites this paper
• Dementia resulting from traumatic brain injury: what is the pathology?

  2012cites this paper
• Characterization of the role of the antioxidant proteins metallothioneins 1 and 2 in an animal model of Alzheimer’s disease

  2012cites this paper
• Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy.

  2012cites this paper
• MD beta-amyloid in alzheimer ’ s Disease Current and Emerging Implications for Diagnosis and Treatment

  2012cites this paper
• Synthesis of stemofoline analogues as acetylcholinesterase inhibitors

  2012cites this paper
• 3‐(2,4‐Dimethoxybenzylidene)‐anabaseine: A promising candidate drug for Alzheimer's disease?

  2012cites this paper
• Bifunctional phenolic-choline conjugates as anti-oxidants and acetylcholinesterase inhibitors

  2011cites this paper
• Mechanism of copper(II)-induced misfolding of Parkinson's disease protein

  2011cites this paper
• Yeast as a Model for Studying A Aggregation, Toxicity and Clearance

  2011cites this paper
• Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models

  2010cites this paper
• eIF4A Inhibition Allows Translational Regulation of mRNAs Encoding Proteins Involved in Alzheimer's Disease

  2010cites this paper
• Astrocytes in Alzheimer’s disease

  2010cites this paper
• [Conformational regulation of amyloid beta-peptide by lipid membranes and metal ions].

  2010cites this paper
• Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.

  2010cites this paper
• Site-Activated Chelators Derived from Anti-Parkinson Drug Rasagiline as a Potential Safer and More Effective Approach to the Treatment of Alzheimer’s Disease

  2010cites this paper
• Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics

  2010cites this paper
• Stem cell transplantation for neurometabolic and neurodegenerative diseases.

  2010cites this paper
• Murine models of Alzheimer's disease and their use in developing immunotherapies.

  2010cites this paper
• Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples

  2010cites this paper
• Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy.

  2009cites this paper